Dendreon gains on revelations of European plans for Provenge
This article was originally published in Scrip
Executive Summary
Jumping ahead of its presentation at the JP Morgan Healthcare Conference in San Francisco this week, US biotech Dendreon revealed 7 January that it expects to file its European marketing authorization application for its prostate cancer immunotherapy Provenge (sipuleucel-T) before the end of this year or early 2012 relying on the same data it used for its FDA approval.